Post

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

MediLink Therapeutics has announced early data with a HER3 antibody drug conjugate (ADC) that the biotech is codeveloping with BioNTech, …

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

Merck & Co (MSD) has announced positive data for its antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan from two studies that …

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Amongst abstracts announced yesterday for the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting was positive data from a …

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

Verastem Oncology has reported positive initial results from an ongoing Phase I/II trial investigating kinase inhibitor avutometinib for the treatment …

FDA advisory committee reviews Novo Nordisk insulin icodec for T1D

The US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee is set to hold a meeting to assess …